Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Application save search
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Published: 2024-02-14 (Crawled : 13:00) - prnewswire.com
CTXR | $0.7329 -2.85% -2.93% 1.3M
|
Health Technology
|
| O: 8.82%
H: 5.57%
C: 4.31%
t-cell license treatment pharmaceuticals application
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
Published: 2024-01-05 (Crawled : 14:00) - globenewswire.com
SANA | $7.96 4.6% 4.4% 2.1M
|
|
| O: 2.04%
H: 10.8%
C: 2.0%
sc262 fda drug clearance application
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3783 10.74% 9.7% 300K
|
Health Technology
|
| O: 10.19%
H: 21.97%
C: -18.5%
FBIO | $1.76 0.57% 0.57% 150K
|
Health Technology
|
| O: -0.53%
H: 2.93%
C: -4.26%
mb-109 fda mb-101 cell treatment application car-t glioblastoma
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Published: 2023-10-18 (Crawled : 12:00) - globenewswire.com
CRBU | $4.005 4.03% 3.87% 1.4M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: -5.35%
cb-012 fda cell treatment clearance application car-t leukemia therapy
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies
Published: 2023-07-05 (Crawled : 13:00) - biospace.com/
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: 8.67%
H: 13.2%
C: -9.57%
cd19 fda drug cell clearance application car-t therapeutics therapy
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
Published: 2023-05-10 (Crawled : 11:00) - globenewswire.com
ACHL | $0.7827 -0.03% -0.03% 430K
|
Manufacturing
|
| O: 5.0%
H: 0.0%
C: -9.42%
cell application platform
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
Published: 2023-05-09 (Crawled : 11:00) - globenewswire.com
ADPT | $2.52 5.0% 4.76% 2.1M
|
Commercial Services
|
| O: 0.76%
H: 9.17%
C: 5.41%
fda drug t-cell application therapy
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
Published: 2023-04-19 (Crawled : 13:00) - biospace.com/
ENLV | News | $1.28 -3.03% -3.13% 51K
|
Health Technology
|
| O: 2.76%
H: 2.35%
C: -2.01%
patent t-cell application therapy
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-04-03 (Crawled : 19:00) - biospace.com/
SNGX | $0.408 -5.34% -5.64% 620K
|
Health Technology
|
| O: -3.55%
H: 11.45%
C: 6.32%
fda drug t-cell treatment meeting application
Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-03-09 (Crawled : 13:00) - prnewswire.com
SNGX | $0.408 -5.34% -5.64% 620K
|
Health Technology
|
| O: -2.09%
H: 14.23%
C: 8.9%
treatment fda drug meeting t-cell application
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
Published: 2023-02-23 (Crawled : 15:00) - biospace.com/
BCAB | $2.17 3.09% 3.0% 870K
|
|
| O: -0.63%
H: 2.22%
C: -8.25%
ba3182 treatment fda clearance drug t-cell application
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-02-14 (Crawled : 13:00) - prnewswire.com
SNGX | $0.408 -5.34% -5.64% 620K
|
Health Technology
|
| O: -31.38%
H: 19.35%
C: 19.35%
treatment fda drug t-cell application
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
Published: 2023-01-26 (Crawled : 23:00) - biospace.com/
SANA | $7.96 4.6% 4.4% 2.1M
|
|
| O: 1.49%
H: 1.05%
C: -3.15%
sc291 fda clearance drug application therapy
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published: 2023-01-24 (Crawled : 16:00) - biospace.com/
CGEM | $15.61 -0.32% -0.32% 950K
|
|
| O: 1.43%
H: 5.09%
C: 4.05%
cln-978 treatment fda clearance drug t-cell application
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
Published: 2022-12-15 (Crawled : 13:00) - prnewswire.com
SNGX | $0.408 -5.34% -5.64% 620K
|
Health Technology
|
| O: 7.78%
H: 11.68%
C: 5.29%
treatment fda drug t-cell application submission
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
Published: 2022-12-01 (Crawled : 13:00) - prnewswire.com
CTXR | $0.7329 -2.85% -2.93% 1.3M
|
Health Technology
|
| O: 0.85%
H: 8.47%
C: 4.24%
treatment drug t-cell application license food
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
Published: 2022-09-28 (Crawled : 13:00) - biospace.com/
CTXR | $0.7329 -2.85% -2.93% 1.3M
|
Health Technology
|
| O: 1.69%
H: 5.83%
C: 0.83%
treatment drug t-cell application license food
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
Published: 2022-09-06 (Crawled : 13:00) - globenewswire.com
ENLV | News | $1.28 -3.03% -3.13% 51K
|
Health Technology
|
| O: 4.46%
H: 0.0%
C: -7.24%
patent application therapy
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
Published: 2022-06-20 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
| Email alert
Add to watchlist
application therapy
Global Cell & Gene Therapy Market Research Report 2022: Expanding Application for Cell & Gene Therapies & Growing Demand for CAR T- Cell Therapies
Published: 2022-02-01 (Crawled : 21:00) - prnewswire.com
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.53%
H: 0.21%
C: -0.07%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: 0.0%
ema application gene therapy research cel gene therapies report therapy growing t-cell
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.